Coherus Oncology (CHRS) Receivables - Net (2013 - 2026)

Coherus Oncology (CHRS) has 13 years of Receivables - Net data on file, last reported at $22.1 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net fell 63.52% year-over-year to $22.1 million; the trailing twelve-month figure through Mar 2026 stood at $22.1 million (down 63.52% YoY), and the FY2025 full-year result was $17.8 million, down 84.0% from the prior year.
• Receivables - Net grew to $22.1 million in Q1 2026, from $17.8 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $260.5 million in Q4 2023 to a low of $5.1 million in Q2 2025.
• A 5-year average of $116.1 million and a median of $111.3 million in 2024 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net soared 148.33% in 2024 and tumbled 97.08% in 2025, its largest moves.
• Tracing CHRS's Receivables - Net over 5 years: stood at $110.0 million in 2022, then surged by 136.92% to $260.5 million in 2023, then plunged by 57.27% to $111.3 million in 2024, then slumped by 84.0% to $17.8 million in 2025, then grew by 23.85% to $22.1 million in 2026.
• Business Quant data shows CHRS's Receivables - Net at $22.1 million in Q1 2026, $17.8 million in Q4 2025, and $9.2 million in Q3 2025.